U.S. Department of Commerce Patent and Trademark Office

Serial No. Atty. Docket No. 50875-DA/JPW/AJD/AG 09/888,938 Applicants: Graham P. Allaway et al.

RMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date Group June 25, 2001

U.S. PATENT DOCUMENTS

Examiner Initial		Do	eum	ent	Nui	mbe	r		Date	Name	Class	Subclass	Filing Date if Appropriate		
	US	6	2	6	5	1	8	4	7/24/01	Gray et al.;					
	US	6	2	6	8	4	7	7	7/31/01	Gray et al.;					
	US	6	7	9	7	8	1	1	9/28/04	Gray et al.;					
	US	6	8	0	0	7	2	9	10/5/04	Li et al.;					
	US	6	5	1	1	8	2	6	1/28/03	Li et al.;					
	US	6	7	4	3	5	9	4	6/1/04	Li et al.;					
	US	6	0	2	5	1	5	4	10/5/04	Li et al.;					
	US	6	4	4	8	3	7	5	9/10/02	Samsom et al.;					
	US	6	6	9	2	9	3	8	2/17/04	Samsom et al.;					
	US	6	8	0	0	4	4	7	10/5/04	Samsom et al.;					
	US	20	01	00	00	2	4	1	04/12/02	Li et al.;					
			04	01	51	7	1	9	08/8/04	Li et al.;					
	US	20	03	01	66	0	2	4	09/4/03	Rosen et al.;					
	US	_		00			3	4	05/23/02	Rosen et al.;	1				
	us	_		00	_		8	6	04/25/02	Rosen et al.;					
		<u> </u>	1:					_		PATENT DOCUMENTS	<u> </u>				
	Document Number								Date	Country	Class	Subclass	Transl		
		<u> </u>											Yes	No	
		0	1	5	8		1	5	08/16/01	PCT;		ļ	ļ		
	wo		1	+			1	6	08/16/01	PCT;			ļ		
	wo	_	6	3			3	7	12/12/96	PCT;	 		-		
	wo	-	7	2	2	+	9	8	06/26/97	PCT;	ļ <u>.</u>				
	WO		7	+	_		1	9	09/4/97	PCT;	<u> </u>	 	ļ		
	WO	+	0	6			1	2	08/22/02	PCT;	 		-	<u> </u>	
	WO	+	7	4	4		5	5	11/27/97	PCT;	 	<u> </u>			
	EP EP	9	6	8		00		9	08/6/96 03/1/96	EPO; EPO;	<u> </u>	+	+	<u> </u>	
	EP	 	P	₽	1/0	00	21	1	03/1/90	EFO,	 		+		
	-	┼	├	+	┢	-		╁	_		 		1		
	<u> </u>	1	_	TI		L		ATE	NITEC (Tl	ing Author, Title, Date, 1	Doutinant I	Pages Eta)	_! !	1	
		Б								tion of HIV-1 infection			v a deletic	on alle	
											and progre		, a deletic	Jii aire	
		of the CKR5 structural gene, Science 273: 1856-1862; He, Jianglin et al. (1997) CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia, Natu 385: 645-649; Mackay, C.R. (1996) Chemokine receptors and T cell chemotaxis, J. Exp. Med. 184: 799-802													
		Ma	DOT	t, C	K. .J.	(19 et a	(0 <u>9</u> 1. (<u>Une</u> 199	6) Molecul	ar cloning and function	axis, J. EXI	erization of a r	ovel hur	nan C	
		Ch	emo	kin	e Re	ecep	tor	(CC	R5) for RAN	NTES, MIP-1β, and MIP-	la, J. Biol.	Chem. 271: 171	61-1716	6;	
									Molecular c . 35: 3362-31	loning and functional exp 367: and	ression of	a new human	CC-Che	mokit	
	 									tion of mimory UIV 1	120 -1		the che	مادند	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

receptor CCR-5, Nature 384: 179-183.

EXAMINER

Wu, L. et al., CD4-induced interaction of primary HIV-1 gpl20 glycoproteins with the chemokine

Applicants: Graham P. Allaway et al.

Serial No.: 09/888,9 18 Filed: June 25, 2001

Exhibit B

Page 2 of 2

												ket No. A/JPW/AJD/A(Serial No. 09/888,938	
INFORMATION DISCLOSURE CITATION												Applicants: Graham P. Allaway et al.			
		111	r O		e se		Filing Date June 25, 2001								
	_								U.S. PA	TENT DOCUMENTS	S				
Examiner Initial	Document Number								Date	Name	Class	Subclass	Filing I		
	us	20	02	01	50	8	8	8	10/17/02	Gray et al.;					
	US	20	04	02	30	0	3	7	11/11/04	Gray et al.					
	US	20	04	01	61	7	3	9	08/19/04	Samsom et al.;					
	US		04	01	11	01		7	06/10/04	Samsom et al.;					
	us		05	01	54	1	9	3	07/14/05	Roschke et al.;					
	us	20	03	01	00	0	5	8	05/29/03	Roschke et al.;					
				1		Τ	1	T							
									FOREIGN	PATENT DOCUME	NTS				
		Do	cum	ent	Nu	mb	er		Date	Country	Class	Subclass	Translation		
													Yes	No	
	CA	19	97	22	16	9	9	0	11/27/97	Canada;					
	EP	0	8	1	5	1	3	7	1/1/98	EPO;					
	EP	1	1	9	9	3	6	0	04/24/02	EPO;					
	EP	1	1	4	5	7	2	1	10/17/01	EPO;					
	EP	1	1	4	6	0	5	5	10/17/01	EPO;		 _	\downarrow		
	EP	1	1	4	6	1	2	2	10/17/01	EPO;		·			
	EP	1	1_	4	8	1	2	6	10/24/01	EPO;		ļ			
	EP	1	1	4	8	1	2	7	10/24/01	EPO;			-		
	EP	1	1	4	9	5	8	2	10/31/01	EPO;					
	EP	1	4	8	2	0	4 8	2	12/1/04	EPO;		 			
	EP	0	8	8	3	6		7	12/16/98	EPO;					
			0	TH	ER	DO	CUI	ME	NTS (Inclu	ding Author, Title, Da	te, Pertinent I	Pages, Etc.)		- · · · - · · · · · · · · · · · · · · ·	
- -	┢	+						-							
	 	+											-		
		+									***************************************			-	
		†													
		1								****					
EXAMINER									DATE CONSIDERED						
									or not citation is nmunication to	s in conformance with MPEP applicant.	609: Draw line thr	ough citation if not i	n conformat	nce and	